AIRS
AirSculpt Technologies, Inc.2.5700
-0.0600-2.28%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
160.46MP/E (TTM)
-Basic EPS (TTM)
-0.30Dividend Yield
0%Recent Filings
8-K
Doyle named Non-Exec Chairman
AirSculpt Technologies appointed Michael Doyle as Class III director and Non-Executive Chairman effective November 14, 2025. Doyle, ex-CEO of Surgery Partners where he scaled from 3 to over 175 locations, brings multi-site healthcare expertise and prior ties to AirSculpt's predecessor. No compensation. He stands for election in 2027.
8-K
Q3 miss, CFO hire, guidance cut
AirSculpt reported Q3 revenue down 17.8% to $35.0M on 15.2% fewer cases at 2,780, with Adjusted EBITDA slipping to $3.0M from $4.7M amid $7.1M impairments from Salesforce and London closure. Updated 2025 guidance targets $153M revenue, $16M Adjusted EBITDA. Hired Michael Arthur as CFO effective January 5, 2026, with $400K salary, $100K sign-on cash, $600K equity. Leadership bolsters finance amid sales pressure.
10-Q
Q3 FY2025 results
AirSculpt's Q3 revenue fell 17.8% y/y to $35.0M from $42.5M, with cases down 15.2% to 2,780, while cost of service dropped 16.3% to keep gross margins steady near 42% of revenue; operating loss widened to $9.8M from $3.7M due to $7.1M impairments on Salesforce project ($4.6M) and London facility closure ($2.3M plus $1.0M rent acceleration). Net loss hit $9.5M or $(0.15) per diluted share on 62.4M shares, versus $(0.10) last year—EPS reconciles cleanly, no anti-dilution. Cash stood at $5.4M with $5.0M revolver availability; term debt trimmed to $56.9M (8.82% rate, due May 2027) after $12.9M paydown funded by June's $13.8M equity raise. Free cash flow not disclosed in the 10-Q. London exit sharpens U.S. focus. Debt covenants loom tight.
8-K
Exec chairman resigns cleanly
8-K
Q2 revenue dips, CFO retiring
AirSculpt Technologies reported Q2 2025 results with revenue down 13.7% to $44.0 million and case volume off 14.1% from last year, yet net loss narrowed to $0.6 million from $3.2 million. The company piloted skin tightening for GLP-1 users and expanded financing, while trimming debt by $16 million post-stock offering. CFO Dennis Dean plans retirement but stays until a successor arrives. Guidance holds at $160-170 million revenue and $16-18 million Adjusted EBITDA. Leadership transition looms.
IPO
Website
Employees
Sector
Industry
ALUR
Allurion Technologies, Inc.
1.54+0.02
AMS
American Shared Hospital Servic
2.13-0.01
ARDT
Ardent Health, Inc.
8.93+0.03
BDMD
Baird Medical Investment Holdin
1.37+0.02
FCHS
First Choice Healthcare Solutio
0.01+0.00
HCA
HCA Healthcare, Inc.
469.79-7.19
INMD
InMode Ltd.
14.48+0.15
PAIYY
Aesthetic Medical International
0.13+0.00
SGRY
Surgery Partners, Inc.
15.52+0.08
VERO
Venus Concept Inc.
2.26+0.59